KR101718748B1 - Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법 - Google Patents

Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법 Download PDF

Info

Publication number
KR101718748B1
KR101718748B1 KR1020147012146A KR20147012146A KR101718748B1 KR 101718748 B1 KR101718748 B1 KR 101718748B1 KR 1020147012146 A KR1020147012146 A KR 1020147012146A KR 20147012146 A KR20147012146 A KR 20147012146A KR 101718748 B1 KR101718748 B1 KR 101718748B1
Authority
KR
South Korea
Prior art keywords
delete delete
antibody
vegf
seq
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147012146A
Other languages
English (en)
Korean (ko)
Other versions
KR20140095481A (ko
Inventor
리 장
Original Assignee
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파아마슈티컬스, 인크. filed Critical 리제너론 파아마슈티컬스, 인크.
Publication of KR20140095481A publication Critical patent/KR20140095481A/ko
Application granted granted Critical
Publication of KR101718748B1 publication Critical patent/KR101718748B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020147012146A 2011-11-10 2012-11-09 Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법 Active KR101718748B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161557939P 2011-11-10 2011-11-10
US61/557,939 2011-11-10
US201261609968P 2012-03-13 2012-03-13
US61/609,968 2012-03-13
US201261613538P 2012-03-21 2012-03-21
US61/613,538 2012-03-21
PCT/US2012/064311 WO2013071016A2 (en) 2011-11-10 2012-11-09 Methods of inhibiting tumor growth by antagonizing il-6 receptor

Publications (2)

Publication Number Publication Date
KR20140095481A KR20140095481A (ko) 2014-08-01
KR101718748B1 true KR101718748B1 (ko) 2017-03-22

Family

ID=47179020

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012146A Active KR101718748B1 (ko) 2011-11-10 2012-11-09 Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법

Country Status (20)

Country Link
US (3) US20130122003A1 (enExample)
EP (1) EP2776468B1 (enExample)
JP (3) JP6144689B2 (enExample)
KR (1) KR101718748B1 (enExample)
CN (1) CN103930443B (enExample)
AR (1) AR088671A1 (enExample)
AU (2) AU2012335596B2 (enExample)
BR (1) BR112014011211A2 (enExample)
CA (1) CA2853836C (enExample)
IL (2) IL231854A (enExample)
IN (1) IN2014CN02923A (enExample)
JO (1) JO3370B1 (enExample)
MX (1) MX357837B (enExample)
MY (1) MY163953A (enExample)
RU (1) RU2648150C2 (enExample)
SG (1) SG11201401286QA (enExample)
TW (3) TW201806620A (enExample)
UY (1) UY34444A (enExample)
WO (1) WO2013071016A2 (enExample)
ZA (1) ZA201402414B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
WO2015000181A1 (zh) * 2013-07-05 2015-01-08 华博生物医药技术（上海）有限公司 新型重组融合蛋白及其制法和用途
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
EP3161000A4 (en) * 2014-06-28 2018-05-02 Kodiak Sciences Inc. Dual pdgf/vegf antagonists
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016196377A1 (en) * 2015-05-29 2016-12-08 Merrimack Pharmaceuticals, Inc. Combination cancer therapies
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
CN112203679A (zh) * 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
AU2019235782A1 (en) 2018-03-14 2020-10-08 Celledit Llc Modification of immune cells for reducing toxicity and uses thereof in adoptive cell therapy
CN108567981A (zh) * 2018-07-17 2018-09-25 漯河医学高等专科学校 白细胞介素-6的拮抗剂在制备抑制Notch-1蛋白表达、治疗胰腺癌的药物中的应用
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN113677356A (zh) * 2019-01-07 2021-11-19 湖南思为康医药有限公司 用于降低毒性的共表达嵌合抗原受体和il-6拮抗剂的修饰免疫细胞及其在过继细胞疗法中的用途
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
EP4298127A4 (en) * 2021-02-27 2025-04-23 Eluminex Biosciences (Suzhou) Limited Antibody fusion proteins targeting il-6 receptor and angiogenic factors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670373A (en) 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
CA1341152C (en) 1988-01-22 2000-12-12 Tadamitsu Kishimoto Receptor protein for human b cell stimulatory factor-2
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5888510A (en) 1993-07-21 1999-03-30 Chugai Seiyaku Kabushiki Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
ATE214602T1 (de) 1994-12-29 2002-04-15 Chugai Pharmaceutical Co Ltd Verstärker eines anti-tumoragens beinhaltend einen il-6 antagonisten
US5795695A (en) 1996-09-30 1998-08-18 Xerox Corporation Recording and backing sheets containing linear and cross-linked polyester resins
BRPI0011407B8 (pt) * 1999-06-08 2021-05-25 Regeneron Pharma molécula de ácido nucléico quimérica, polipeptídeo de fusão, vetor de expressão, sistema de vetor hospedeiro, e, métodos de produzir um polipeptídeo de fusão
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) * 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
ATE316531T1 (de) 1999-10-07 2006-02-15 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
AU2000279624A1 (en) 2000-10-27 2002-05-15 Chugai Seiyaku Kabushiki Kaisha Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
KR20060079180A (ko) * 2003-07-02 2006-07-05 노보 노르디스크 에이/에스 Ｎｋ 세포 활성을 조절하기 위한 조성물 및 방법
BRPI0415505A (pt) 2003-10-17 2006-12-12 Chugai Pharmaceutical Co Ltd agente terapêutico para mesotelioma
US20090269335A1 (en) 2005-11-25 2009-10-29 Keio University Therapeutic agent for prostate cancer
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
PL2374818T3 (pl) 2006-06-02 2013-05-31 Regeneron Pharma Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6
WO2008154927A1 (en) * 2007-06-21 2008-12-24 Genmab A/S Novel methods for treating egfr-associated tumors
US8323649B2 (en) * 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
CN102292449B (zh) * 2008-11-25 2016-03-30 奥尔德生物制药公司 预防或治疗血栓形成的il-6拮抗剂
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
International Journal of Cancer, Vol 125, Pages 1054-1064(2009)*

Also Published As

Publication number Publication date
ZA201402414B (en) 2015-03-25
EP2776468A2 (en) 2014-09-17
TW201806620A (zh) 2018-03-01
TW201332569A (zh) 2013-08-16
RU2648150C2 (ru) 2018-03-22
US9409990B2 (en) 2016-08-09
US20130122003A1 (en) 2013-05-16
JP2017095489A (ja) 2017-06-01
SG11201401286QA (en) 2014-05-29
CN103930443B (zh) 2017-08-04
TWI604852B (zh) 2017-11-11
JP6144689B2 (ja) 2017-06-07
US20170022279A1 (en) 2017-01-26
MY163953A (en) 2017-11-15
WO2013071016A3 (en) 2013-07-25
WO2013071016A2 (en) 2013-05-16
JO3370B1 (ar) 2019-03-13
RU2014118739A (ru) 2015-12-20
IN2014CN02923A (enExample) 2015-07-03
KR20140095481A (ko) 2014-08-01
CA2853836A1 (en) 2013-05-16
IL248620A0 (en) 2016-12-29
TW201716776A (zh) 2017-05-16
US20140322215A1 (en) 2014-10-30
MX357837B (es) 2018-07-26
EP2776468B1 (en) 2018-01-24
JP6283754B2 (ja) 2018-02-21
IL231854A0 (en) 2014-05-28
UY34444A (es) 2013-05-31
JP2014534237A (ja) 2014-12-18
AU2012335596B2 (en) 2018-05-17
AU2018203666A1 (en) 2018-06-14
CN103930443A (zh) 2014-07-16
JP2018083841A (ja) 2018-05-31
AR088671A1 (es) 2014-06-25
MX2014004886A (es) 2014-07-09
IL231854A (en) 2016-11-30
BR112014011211A2 (pt) 2017-04-25
AU2012335596A1 (en) 2014-05-22
CA2853836C (en) 2019-07-23

Similar Documents

Publication Publication Date Title
KR101718748B1 (ko) Ｉｌ-6 수용체의 길항에 의한 종양 성장의 저해 방법
KR102338453B1 (ko) Ｖｅｇｆ 길항제와 항-ｃｔｌａ-4 항체의 조합물을 포함하는 조성물 및 방법
KR102460525B1 (ko) 항-tim-3 항체 및 그의 용도
US12435133B2 (en) Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof
KR20210142659A (ko) Egfr×cd28 다중특이성 항체
CA2451955C (en) Antibodies to opgl
AU2019332708A1 (en) Anti-PD-1 and anti-VEGFA bifunctional antibody, pharmaceutical composition thereof and use thereof
CN101102786A (zh) 施用并利用vegf抑制剂治疗人类癌症的方法
KR20140108527A (ko) Ｇｄｆ8 및/또는 액티빈 ａ를 특이적으로 길항함으로써 근육량과 근육 강도를 증가시키는 조성물 및 방법
KR20170028441A (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
KR20150082327A (ko) Ｄｌｌ4 길항제로 난소암을 치료하는 방법
AU2022233411A1 (en) Pharmaceutical combination containing anti-pd-1-anti-vegfa bispecific antibody, and use thereof
CN114423784A (zh) 多价fzd和wnt结合分子及其用途
KR20230024408A (ko) 항-cldn-18.2 항체 및 그 용도
KR20230135627A (ko) 항-PDGF-b 항체 및 폐동맥 고혈압 (PAH)을 치료하기 위한 사용 방법
RU2829997C1 (ru) Антитело к cldn-18.2 и его применение
AU2015264940B2 (en) Antibodies to OPGL
HK1116053A (en) Use of vegf inhibitors for the treatment of human cancer
HK1197681B (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor
HK1197681A (en) Methods of inhibiting tumor growth by antagonizing il-6 receptor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140502

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140820

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160420

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20161128

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160420

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20161128

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160720

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20140820

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170120

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20161229

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20161128

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160720

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20140820

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170316

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170317

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200302

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210226

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220223

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 8

End annual number: 8